Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QVV0
Tue, 19.09.2023
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101
First four patient cohorts and dose levels have been completed and proved to be safe and well tolerated
Enrollment for fifth cohort with a dose of 100 µg/kg has already started
Patient from third cohort continues to be dosed and shows no pr [ … ]
Tue, 08.08.2023
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma’s Partner Takeda Reached Development Milestone
Ladenburg, Germany, 8 August 2023 – Heidelberg Pharma AG (FSE: HPHA) announced today that its partner Takeda reached a development milestone for starting a GLP (Good Laboratory Practice) toxicology study for an Antibody Targeted Amanitin Conjugate. Upon achievement of [ … ]
Thu, 13.07.2023
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
Clinical trial with HDP-101 continues with adjusted protocol and larger number of study sites in Europe
Patient from 3rd cohort continues to be dosed and shows stable disease
Partnership with Magenta terminated due to clinical events and strategy change [ … ]
Thu, 13.07.2023
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
Clinical trial with HDP-101 continues with adjusted protocol and larger number of study sites in Europe
Patient from 3rd cohort continues to be dosed and shows stable disease
Partnership with Magenta terminated due to clinical events and strategy change [ … ]
Thu, 25.05.2023
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma reports on the results of the Annual General Meeting 2023
Ladenburg, Germany, 25 May 2023 - Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 96,30 % and 99,99 %) at today's ordinary virtual Annual [ … ]
Thu, 25.05.2023
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma reports on the results of the Annual General Meeting 2023
Ladenburg, Germany, 25 May 2023 - Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 96,30 % and 99,99 %) at today's ordinary virtual Annual [ … ]
Fri, 05.05.2023
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma appoints Chief Financial Officer
Ladenburg, Germany, 5 May 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Walter Miller has been appointed Chief Financial Officer effective 1st May 2023. Dr. Jan Schmidt-Brand, who has served in a dual role since 2014, will remain Spokesman of the Management Board/CEO [ … ]
Fri, 05.05.2023
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma appoints Chief Financial Officer
Ladenburg, Germany, 5 May 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Walter Miller has been appointed Chief Financial Officer effective 1st May 2023. Dr. Jan Schmidt-Brand, who has served in a dual role since 2014, will remain Spokesman of the Management Board/CEO [ … ]
Thu, 13.04.2023
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
Initial findings of HDP-101 presented at ASH Annual Meeting
Signing of a partnership with Binghamton University
Termination agreement signed with Magenta
Financials in line with planning
Ladenburg, Germany, 4 April 2023 - Heidelberg Pharma AG (FSE: HPHA) today [ … ]
Thu, 13.04.2023
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
Initial findings of HDP-101 presented at ASH Annual Meeting
Signing of a partnership with Binghamton University
Termination agreement signed with Magenta
Financials in line with planning
Ladenburg, Germany, 4 April 2023 - Heidelberg Pharma AG (FSE: HPHA) today [ … ]